{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:46:46Z","timestamp":1793375206113,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Serum troponins and CK-MB (creatine kinase-MB) are readily detectable and reliable cardiac-specific biomarkers of subclinical myocardial injury. This study explores the roles of cTnI (cardiac troponin I) and CK-MB in hypertrophic cardiomyopathy (HCM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This study included 1045 patients with HCM who had baseline cTnI and CK-MB measurements at Fuwai Hospital between 1999 and 2019. Patients were excluded if they had undergone percutaneous coronary intervention or coronary artery bypass grafting, or had renal failure. Five end points were studied: all-cause death, cardiovascular death, noncardiovascular death, sudden cardiac death, and other cardiovascular death. Cox regression was used to assess the associations of cTnI and CK-MB levels with outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Nine hundred seventy patients with available follow-up data were finally analyzed (mean age, 49.3 years; 36.4% female). During the median 4.3-year follow-up period, 87 patients reached the end points. Higher cTnI (per 0.05 ng\/mL increase) and CK-MB (per 1 IU\/L increase) levels were associated with increased risks of all-cause death (cTnI: adjusted hazard ratio [HR], 1.038,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001; CK-MB: adjusted HR, 1.021,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.004), cardiovascular death (cTnI: adjusted HR, 1.040,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001; CK-MB: adjusted HR, 1.025,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.006), and sudden cardiac death (cTnI: adjusted HR, 1.045,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001; CK-MB: adjusted HR, 1.032,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001). Patients with elevated levels of both cTnI and CK-MB had worse prognoses than patients with an elevated level of either biomarker alone and patients who did not have an elevated level of either biomarker. Addition of the binary indicator elevation of both cTnI and CK-MB significantly improved the discrimination and reclassification abilities of the standard HCM Risk- sudden cardiac death model (C statistics:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.002; net reclassification improvement, 0.652; integrated discrimination improvement, 0.064).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Comprehensive evaluations of biomarkers of myocardial injury, cTnI and CK-MB, have considerable value for predicting adverse outcomes among patients with HCM. Routine cTnI and CK-MB assessments may help to guide implantable cardioverter defibrillator implantation for primary prevention in HCM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circoutcomes.123.010243","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T05:00:16Z","timestamp":1705640416000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Role of Biomarkers of Myocardial Injury to Predict Adverse Outcomes in Hypertrophic Cardiomyopathy"],"prefix":"10.1161","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3217-0245","authenticated-orcid":true,"given":"Yu","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Cardiovascular Disease (Y. Zhang, C.Z., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-5530","authenticated-orcid":true,"given":"Minghao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology (M.L., Y. Zou), Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channa","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cardiovascular Disease (Y. Zhang, C.Z., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-4397","authenticated-orcid":true,"given":"Yubao","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Cardiology (M.L., Y. Zou), Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianming","family":"Kang","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Ward (L.K., L.S.), Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-9321","authenticated-orcid":true,"given":"Lei","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cardiovascular Disease (Y. Zhang, C.Z., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."},{"name":"National Clinical Research Center of Cardiovascular Diseases (L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."},{"name":"Cardiomyopathy Ward (L.K., L.S.), Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-311387"},{"key":"e_1_3_3_3_2","volume-title":"Clinical Methods: The History, Physical, and Laboratory Examinations","author":"Cabaniss CD","year":"1990","unstructured":"Cabaniss, CD. Creatine Kinase. In: Walker, HK, Hall, WD, Hurst, JW, eds. Clinical Methods: The History, Physical, and Laboratory Examinations. Butterworths Copyright \u00a9 1990, Butterworth Publishers, a division of Reed Publishing; 1990."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"e_1_3_3_5_2","volume-title":"Myocardial Infarction Serum Markers StatPearls","author":"Basit H","year":"2022","unstructured":"Basit, H, Huecker, MR. Myocardial Infarction Serum Markers StatPearls. StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC; 2022."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1710575"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.019"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa023"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20622"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-020-01921-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/echo.13645"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-020-01933-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23425"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0872"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000938"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2014.03.001"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12082029"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021210914"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.120.050384"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.144"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(86)80181-4"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2000.16659"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.657023"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.050"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2021.04.040"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.055"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.123.010243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:14:44Z","timestamp":1748538884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.123.010243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.123.010243"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.123.010243","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}